Merit Medical (MMSI) Systems announced the US commercial release of the Resilience Through-the-Scope Esophageal Stent. The Resilience stent is the newest product in Merit’s Endoscopy portfolio, joining a comprehensive offering of treatment options for patients with disease in the esophagus. The new stent is indicated for treatment of esophageal fistulas and strictures caused by malignant tumors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical Earnings Call Highlights Profitable Growth
- Wells Fargo downgrades Merit Medical on 2026 guidance uncertainty
- Merit Medical downgraded to Equal Weight from Overweight at Wells Fargo
- Merit Medical price target lowered to $104 from $108 at Baird
- Merit Medical price target raised to $109 from $106 at Barrington